Introduction
============

Secondary hyperparathyroidism (SHPT) is a frequently encountered problem in the management of patients with chronic kidney disease (CKD). SHPT has long been associated with poor patient outcomes, including accelerated atherosclerosis and metabolic bone disease \[[@sfx086-B1], [@sfx086-B2]\]. Parathyroidectomy (PTX) in end-stage renal failure (ESRF) is an effective method for normalization of calcium and parathyroid metabolism and for improving renal bone disease. Even though the initial management of SHPT involves medical treatment, ∼10% of patients will eventually require PTX \[[@sfx086-B3]\]. In a study of a cohort of maintenance dialysis patients from the nationwide registry of the Japanese Society for Dialysis Therapy, patients who had undergone PTX had a 34% and 41% lower risk for all-cause and cardiovascular mortality, respectively \[[@sfx086-B4]\]. Our center performs total PTX without autotransplantation to minimize the risk for recurrence and potential SHPT relapse. Despite the widespread practice of PTX, there is a scarcity of data describing the clinical outcomes that occur within 1 year after PTX. In this study we sought to describe the postoperative clinical course for 1 year in patients who had PTX without autoimplantation from January 2010 to February 2014.

Materials and methods
=====================

As per our national dialysis registry, 98% of our dialysis population received thrice weekly dialysis and the treatment duration was 4 h in 99% of the treatments. More than 90% of the patients were prescribed hemodialysis with a blood flow rate of \>250 mL/min. In all, 86.8% of patients received dialysis through a functioning fistula. The mean and median delivered *Kt*/*V* were 1.5 and 1.4, respectively, for hemodialysis patients and 2.0 and 1.9 for those receiving peritoneal dialysis \[[@sfx086-B5]\]. All patients who underwent PTX from January 2010 to February 2014 in a tertiary renal referral center (Serdang Hospital, Malaysia) were included and followed up for 12 months post-PTX. These patients were managed as per our published protocol during their hospitalization for PTX \[[@sfx086-B6]\]. Table [1](#sfx086-T1){ref-type="table"} describes the rate of infusion of calcium gluconate after surgery based on the serum alkaline phosphatase (ALP) level on admission. Preoperative and postoperative serial values of bone parameters such as calcium, phosphorus, ALP and intact parathyroid hormone (iPTH) were measured. Patients' hospitalization and mortality records were retrieved from hospitals and dialysis centers via feedback letters and telephone calls to these centers. The clinical outcomes of interest were all-cause mortality and hospitalization events, including the reasons for admission, duration of stay and fracture rate post-PTX. The normal range of corrected calcium in this study is defined as between 2.1 and 2.6 mmol/L and any readings outside this range are defined as hypocalcemia and hypercalcemia, respectively. The study was approved by the ethics committee and registered under the National Medical Research Register of Malaysia. Table 1.Rate of infusion of calcium gluconate after surgery based on serum ALP level on admissionALP (IU/L)Infusion rate (mL/h)Elemental calcium (mg/day)Dialysate calcium (mmol/L)\>7004034701.75500--7002024291.75\<5001017361.75

Statistical analysis
====================

The characteristics of dialysis patients who underwent PTX were evaluated using mean and standard deviation (SD) for continuous variables and absolute number and percentage for categorical variables. SPSS version 23 (IBM, Armonk, NY, USA) was used for analysis. P-values \<0.05 were considered to be statistically significant.

Results
=======

We identified a total of 115 patients who underwent PTX between January 2010 and February 2014, of which 90 patients fulfilled the inclusion criteria. Patients with incomplete data or those who refused to provide consent were excluded. Table [2](#sfx086-T2){ref-type="table"} describes the baseline characteristics of the PTX patients recruited into the study. The majority of the patients \[*n* = 49 (54.4%)\] were male with a mean age of 46.0 ± 18.0 years. Most patients \[*n* = 81 (90%)\] were doing hemodialysis at the time of PTX and the mean duration of dialysis was 8.0 ± 5.0 years. In all, 12 (13.3%) of the patients had diabetes mellitus. Most patients \[*n* = 86 (95.6%)\] had bone pain and 3 patients (3.3%) had fractures prior to PTX. The majority of patients \[*n* = 83 (92.2%)\] had all four parathyroid glands removed and histopathological findings showed hyperplasia in 83 patients (92.2%). Mean values of serum calcium, phosphate, albumin, ALP and iPTH prior to PTX were 2.40 ± 0.23 mmol/L, 1.92 ± 0.51 mmol/L, 689.60 ± 708.50 U/L and 311.90 ± 171.94 pmol/L, respectively. Table [3](#sfx086-T3){ref-type="table"} compares of the baseline characteristics among included versus excluded PTX patients. The baseline characteristics were comparable. Table 2.Baseline characteristics of included parathyroidectomy patients (*N* = 90)Characteristics*n*%Mean ± SDAge (years)[^a^](#tblfn1){ref-type="table-fn"}46.0 (18.0)Male (%)4954.4Duration of dialysis (years)[^a^](#tblfn1){ref-type="table-fn"}8.0 (5.0)Hemodialysis (%)8190.0Primary disease (%) Hypertension2426.7 Glomerulonephritis1314.4 Diabetes mellitus1213.3 Unknown3538.9 Others[^b^](#tblfn2){ref-type="table-fn"}66.7Symptoms (%) Bone pain8695.6 Fracture33.3 Calciphylaxis11.1Operative findings (%) All four glands removed8392.2 Hyperplasia8392.2 Adenoma77.8Biochemical parameters Calcium (mmol/L)2.40 ± 0.23 Phosphate (mmol/L)1.92 ± 0.51 Albumin (g/L)35.93 ± 5.27 ALP (U/L)[^a^](#tblfn1){ref-type="table-fn"}689.60 (708.50) IPTH (pmol/L)311.90 ± 171.94[^1][^2]Table 3Comparisons of baseline characteristics of all PTX patients (*N* = 115)CharacteristicsIncludedExcludedP-value(*n* = 90)(*n* = 25)Age (years)[^a^](#tblfn3){ref-type="table-fn"}46.0 (18.0)43.5 (15.0)0.776Male (%)54.446.20.456Duration of dialysis (years)[^a^](#tblfn3){ref-type="table-fn"}8.0 (5.0)8.0 (6.5)0.897Hemodialysis (%)90.01000.093Primary disease (%) Hypertension26.77.70.144 Glomerulonephritis14.47.7 Diabetes mellitus13.326.9 Unknown38.950.0 Others6.77.7Symptoms (%)0.550 Bone pain95.6100 Fracture3.30 Calciphylaxis1.10Operative findings (%) All four glands removed92.296.20.696 Histopathology findings Hyperplasia92.288.50.547 Adenoma7.811.50.247Biochemical parameters Calcium (mmol/L)2.40 ± 0.232.40 ± 0.280.727 Phosphate (mmol/L)1.92 ± 0.511.67 ± 0.440.021 Albumin (g/L)35.93 ± 5.2741.69 ± 3.690.063 ALP (U/L)[^a^](#tblfn3){ref-type="table-fn"}689.60 (708.50)483.50 (581.75)0.317 IPTH (pmol/L)311.90 ± 171.94231.47 ± 215.90[^3]

One-year outcomes
-----------------

### Bone parameters

The iPTH level showed an abrupt reduction after PTX. By 1-year post-PTX, 90 patients (100%) had serum iPTH levels \<8 pmol/L and 28 patients (31.1%) had undetectable levels. Figure [1](#sfx086-F1){ref-type="fig"} shows the mean ALP level over time after PTX. The mean ALP values show a gradual decrease and normalization by 1-year post-PTX. One patient had relapsed with hyperparathyroidism from the partially removed parathyroid glands and required a second exploratory PTX procedure.

![Mean ALP level post-PTX (*N* = 90).](sfx086f1){#sfx086-F1}

### Clinical course

Table [4](#sfx086-T4){ref-type="table"} describes the clinical course post-PTX for 1 year. A total of 14 patients had hospitalizations within in 1 year of PTX for various reasons. There were 25 hospital admissions for these 14 patients. The 1-year hospitalization rate was 14%, of which 44% were within the first 90 days. The mean hospital stay was 14.4 ± 18.6 days. The reasons for hospitalization were hypo/hypercalcemia \[*n* = 9 (36.0%)\], sepsis \[*n* = 6 (32%)\] and fluid overload \[*n* = 4 (16%)\]. Hospitalization due to fracture was 4% (*n* = 1) post-PTX. There was no difference in baseline characteristics and biochemical profiles between the hospitalized and nonhospitalized patients (Table [5](#sfx086-T5){ref-type="table"}). The 1-year mortality among patients undergoing PTX was 4.4%, of which 25% were within the first 30 days. Acute coronary syndrome was noted in 25% of patients. Table 4.Clinical course post-PTX (*N*= 90)Events*N* (%)iPTH changes (pmol/L), *n* (%)By 1 year, level \<890 (100)By 1 year, unmeasurable level28 (31.1)Mortality over 1 year, *n* (%)4 (4.4) In first 30 days (%)25 In first 90 days (%)75Causes of death (%) Sepsis75 Acute coronary syndrome25Hospitalization, *n* (%)14 (15.6)Total hospitalizations, *n*25 Hospitalizations in 30 days, *n* (%)10 (40) Hospitalizations in 90 days, *n* (%)11 (44)Days of hospitalization (mean ± SD)14.4 ± 18.6Causes of hospitalization, *n* (%) Hypocalcemia5 (20) Hypercalcemia4 (16) Fluid overload4 (16) Vascular access sepsis4 (16) Other sepsis2 (8) Other vascular access issues3 (12) Fracture1 (4) Stroke1 (4) Acute coronary syndrome1 (4)Table 5Comparison of baseline characteristics of hospitalized patients post-PTXCharacteristicsHospitalizedNon-hospitalizedP-value(*n* = 14)(*n* = 76)Age (years), mean ± SD43.9 ± 14.745.1 ± 12.20.136Male (%)28.659.20.034Duration of dialysis (years), mean ± SD8.9 ± 3.58.7 ± 3.80.470Hemodialysis (%)85.790.80.561Primary disease (%) Hypertension28.626.30.693 Glomerulonephritis21.413.2 Diabetes mellitus7.114.5 Unknown42.938.2 Others07.9Biochemical parameters, mean ± SD Calcium (mmol/L)2.43 ± 0.182.40 ± 0.240.105 Phosphate (mmol/L)1.86 ± 0.491.93 ± 0.520.404 Albumin (g/L)34.8 ± 6.536.1 ± 5.10.388 ALP (U/L)777.1 (468.2)821.6 (541.8)0.885 IPTH (pmol/L)421.1 ± 268.01283.9 ± 129.50.298

Discussion
==========

The Kidney Disease: Improving Global Outcomes (KDIGO) international guideline group recommends that patients with CKD Stages 3--5D with severe hyperparathyroidism who fail to respond to medical therapy should undergo PTX \[[@sfx086-B7]\]. The first PTX for SHPT was performed by Fergusson in 1967. Total PTX without autoimplantation was initially not favored as a treatment for SHPT due to the initial concerns of subclinical hypoparathyroidism. However, Ljutic *et al*. \[[@sfx086-B8]\] followed up a cohort of 43 patients with total PTX without autoimplantation and reported that nearly 8 years after PTX, there was no evidence of occurrence of subclinical hypoparathyroidism or adynamic bone disease. Currently there is a general consensus that total PTX without autotransplantation is comparable to subtotal PTX and total PTX with autoimplantation. The decision to undertake which procedure will depend on the skill of the surgeon and the hospital. Despite the best intention of our surgeon to carry out total PTX in all cases, in 17% of the cases the surgeon failed to locate and remove all glands intraoperatively. The accuracy can be improved via intraoperative PTH assays or Tc99m sestamibi scans, which are not available in our hospital.

Few studies that have focused primarily on the benefits of PTX have shown an improvement in laboratory parameters postoperatively \[[@sfx086-B9]\]. However, there are few papers that describe clinical outcome after PTX. Similar to these studies, we found significant improvement in biochemical bone parameters after PTX. However, we observed several significant clinical outcomes in the first 30 days and up to 1 year after PTX. The most pronounced outcome was a high hospitalization rate of 14% per year, of which 40% happened within 30 days and 44% within 90 days of PTX for various reasons. The mortality rate was 4.4% per year, of which 25% were within 30 days of PTX. One large-scale, observational study from the United States Renal Database System (USRDS) showed a survival benefit post-PTX after 1 year compared with matched controls, with reported mortality rates of 10.4% versus 12.2%. However, the short-term 30-day mortality was elevated (3.1% versus 1.2%) \[[@sfx086-B12]\]. A more recent study by Ishani *et al*. \[[@sfx086-B13]\] using the same USRDS registry found that mortality at 30 days was 2.0% and at 1 year was 9.8%. In this study, our mortality rate was much lower. Our 30-day mortality was 1.1% and at 1 year it was 4.4%. Our improved mortality rate may be attributed to a smaller sample size, improved surgical techniques or more meticulous post-PTX care.

We also found that PTX is associated with significant morbidities. These are mainly related to hospitalizations for hypo/hypercalcemia issues. We are currently tightening our own protocol-driven postoperative care regime so that the readmission of patients due to hypo-/hypercalcemia complications can be further decreased. In addition, we found a lower fracture rate after PTX \[*n* = 1 (1.1%)\] as compared with before PTX \[*n* = 3 (3.3%)\]. The sole fracture that occured after PTX was attributed to a spontaneous vertebral compression fracture secondary to osteoporosis. Our finding is in keeping with the findings of Rudser *et al*. \[[@sfx086-B14]\] who evaluated the risk of fractures after PTX in a nationwide cohort and demonstrated a lower risk compared with matched controls.

Our study has demonstrated that the procedure of PTX does come with small but significant risks of mortality and morbidity. Although PTX is still the treatment of choice in cases of severe SHPT, there may be an increased role for calcimimetics to be considered as nonoperative treatment for SHPT in high cardiac risk patients.

Our study should be interpreted in light of the following limitations. First, our study included only patients undergoing maintenance dialysis. The applicability of our results to other dialysis populations is unknown. Second, our sample size is relatively small and from a single center. We were unable to determine whether the adverse outcomes were due to the PTX procedure or the fact that ESRF patients have an increased morbidity while undergoing elective general surgery procedures \[[@sfx086-B15]\].

Conclusions
===========

We hope that with our reported clinical outcome after PTX will contribute to the understanding of the risks involved, assisting providers and patients in making informed decisions. These data provide essential evidence regarding adverse clinical outcomes related to surgical PTX, which should be recognized when considering this procedure as a treatment option for patients with severe SHPT.
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